[go: up one dir, main page]

AR000555A1 - Uso de composiciones anabolicas para la masa osea en base a cantidades efectivas no toxicas del ácido Ä3-(n,n-dimetilamino)-1-hidroxipropilidenoÜbisfosfonico o la sal monosodica u otra sal farmacéuticamente aceptable del mismo - Google Patents

Uso de composiciones anabolicas para la masa osea en base a cantidades efectivas no toxicas del ácido Ä3-(n,n-dimetilamino)-1-hidroxipropilidenoÜbisfosfonico o la sal monosodica u otra sal farmacéuticamente aceptable del mismo

Info

Publication number
AR000555A1
AR000555A1 AR33481795A AR33481795A AR000555A1 AR 000555 A1 AR000555 A1 AR 000555A1 AR 33481795 A AR33481795 A AR 33481795A AR 33481795 A AR33481795 A AR 33481795A AR 000555 A1 AR000555 A1 AR 000555A1
Authority
AR
Argentina
Prior art keywords
hydroxypropylidene
dimethylamino
bone mass
pharmaceutically acceptable
anabolic
Prior art date
Application number
AR33481795A
Other languages
English (en)
Inventor
S Papapoulos
J L Ferretti
R Labriola
N Mondelo
E Roldan
Original Assignee
Gador Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gador Sa filed Critical Gador Sa
Publication of AR000555A1 publication Critical patent/AR000555A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Nutrition Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Uso de una cantidad efectiva y no-tóxica del ácido [3-(N,N-dimetilamino)-1-hidroxipropilideno]-bis-fosfónico o de la sal monosódica u otra salfarmacéuticamente aceptable para la preparación de un medicamento para la preservación y aumentoanabó lico de la masa ósea y para el mejoramiento de laspropiedades biomecánicas del hueso en humanos u otros animales afectados de pérdida de masa ósea.
AR33481795A 1994-12-28 1995-12-27 Uso de composiciones anabolicas para la masa osea en base a cantidades efectivas no toxicas del ácido Ä3-(n,n-dimetilamino)-1-hidroxipropilidenoÜbisfosfonico o la sal monosodica u otra sal farmacéuticamente aceptable del mismo AR000555A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP94120799 1994-12-28

Publications (1)

Publication Number Publication Date
AR000555A1 true AR000555A1 (es) 1997-07-10

Family

ID=8216571

Family Applications (1)

Application Number Title Priority Date Filing Date
AR33481795A AR000555A1 (es) 1994-12-28 1995-12-27 Uso de composiciones anabolicas para la masa osea en base a cantidades efectivas no toxicas del ácido Ä3-(n,n-dimetilamino)-1-hidroxipropilidenoÜbisfosfonico o la sal monosodica u otra sal farmacéuticamente aceptable del mismo

Country Status (11)

Country Link
EP (1) EP0800397B1 (es)
JP (1) JP3796693B2 (es)
KR (1) KR100385697B1 (es)
AR (1) AR000555A1 (es)
AU (1) AU701258B2 (es)
BR (1) BR9510123A (es)
CA (1) CA2208714C (es)
DE (1) DE69534923T2 (es)
ES (1) ES2262145T3 (es)
WO (1) WO1996019998A1 (es)
ZA (1) ZA9510995B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0753523A1 (en) * 1995-07-10 1997-01-15 Gador S.A. Amino-substituted bisphosphonic acids
DE19719680A1 (de) * 1997-05-09 1998-11-19 Boehringer Mannheim Gmbh Verwendung von Diphosphonsäuren zur präventiven Behandlung von Spätfolgen bei Harnblasenerweiterung oder Harnblasenersatz
DK0891979T3 (da) * 1997-07-15 2005-01-31 Gador Sa Krystallinsk form af N,N-dimethyl-3-amino-1-hydroxypropan-1,1-diphosphonsyre-mononatrium-monohydrat og fremgangsmåde til fremstilling heraf
AR013994A1 (es) * 1998-10-30 2001-01-31 Gador Sa Procedimiento y preparaciones que modulan selectivamente la funcion del osteoblasto para la prevencion y tratamiento de las osteopatias fragilizantes.
WO2000028982A2 (en) * 1998-11-19 2000-05-25 The Board Of Trustees For The University Of Arkansas Increasing bone strength with selected bisphosphonates
MXPA03006565A (es) 2001-01-23 2005-07-29 Gador Sa Composicion comprendiendo bisfosfonatos para la prevencion y/o tratamiento de enfermedades metabolicas de huesos, proceso para preparar tal composicion y el uso de la misma.
KR20120065435A (ko) 2002-05-10 2012-06-20 에프. 호프만-라 로슈 아게 골다공증 치료 및 예방용 비스포스폰산
CA2689504A1 (en) * 2007-06-19 2008-12-24 Albemarle Corporation Processes for manufacturing bisphosphonic acids

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0162510B1 (en) * 1984-04-30 1991-08-28 THE PROCTER & GAMBLE COMPANY Kit for use in the treatment of osteoporosis
WO1992014474A1 (en) * 1991-02-26 1992-09-03 Norwich Eaton Pharmaceuticals, Inc. Methods for the treatment of osteoporosis
HUT68010A (en) * 1991-12-17 1995-05-29 Procter & Gamble Pharma The use of bisphonates and parathyroid hormone for the treatment of osteoporosis
DE69316013T2 (de) * 1992-06-30 1998-07-09 Procter & Gamble Pharma Verwendung von phosphinate zur behandlung der osteoporose
EP0600834A1 (en) * 1992-11-30 1994-06-08 Ciba-Geigy Ag Use of methanebisphosphonic acid derivatives for the manufacture of a medicament for fracture healing
US5366965A (en) * 1993-01-29 1994-11-22 Boehringer Mannheim Gmbh Regimen for treatment or prophylaxis of osteoporosis

Also Published As

Publication number Publication date
EP0800397A1 (en) 1997-10-15
AU701258B2 (en) 1999-01-21
ES2262145T3 (es) 2006-11-16
CA2208714C (en) 2003-10-21
DE69534923T2 (de) 2006-11-23
DE69534923D1 (de) 2006-05-18
CA2208714A1 (en) 1996-07-04
JP3796693B2 (ja) 2006-07-12
ZA9510995B (en) 1997-06-30
BR9510123A (pt) 1997-12-30
EP0800397B1 (en) 2006-04-05
KR100385697B1 (ko) 2003-08-21
JPH11502506A (ja) 1999-03-02
WO1996019998A1 (en) 1996-07-04
AU4434796A (en) 1996-07-19

Similar Documents

Publication Publication Date Title
BG60102B2 (bg) Метод за получаване на 5-флуор-2(((4-циклопропил- метокси-2-пиридинил)метил)тионил)-1н-бензимидазол
BE2011C013I2 (es)
HUT77333A (hu) Triazolilszármazékok és ezek sói vagy fémkomplexei, előállításuk és alkalmazásuk, hatóanyagként ezeket a vegyületeket tartalmazó mikrobicid készítmények
AR035731A1 (es) Un producto desodorante adecuado para su utilizacion sobre el cuerpo humano que comprende acido picolinico y una especie peroxilo o fuente equivalente de la misma. un metodo cosmetico para lograr un beneficio desodorante sobre el cuerpo humano y un metodo para la fabricacion de dicho producto
MD707C2 (ro) Derivaţi ai sulfonilureei, procedeu de obţinere a lor, produse intermediare pentru ei, substanţă pe baza lor cu acţiune erbicidă şi de reprimare a creşterii plantelor, procedeu de combatere a buruienilor
HUT52083A (en) Herbicidal compositions comprising cyclohexenone oxymetres as active ingredient and process for producing the active ingredients
AR000555A1 (es) Uso de composiciones anabolicas para la masa osea en base a cantidades efectivas no toxicas del ácido Ä3-(n,n-dimetilamino)-1-hidroxipropilidenoÜbisfosfonico o la sal monosodica u otra sal farmacéuticamente aceptable del mismo
HUP9900365A3 (en) N-aryl-1,2,4-triazolin-5-on derivatives, preparation and use thereof, insecticide, arachnicide and nematocide compositions containing these compounds as active ingredients
TW372193B (en) Novel pharmaceutical composition for the preparation of a stable powder containing an association of acetylsalicylic acid and metoclopramide as the active ingredient
CA2388244A1 (en) Agents for promoting fattening of animals and method of promoting fattening
HUP9800522A3 (en) Substituted 2-phenylpyridine-derivatives, preparation and use thereof, herbicide, desiccation and defloriation compositions containing these compounds as active ingredients
NZ510360A (en) Fish gelatinous composition for use as an ingredient in tablets
IT1229223B (it) Composizioni veterinarie sinergisticamente attive e procedimento per la loro preparazione.
HUP9802345A3 (en) Pyrazol-4-yl-benzoyl derivatives, preparation and use thereof, herbicide compositions containing these compounds as active ingredients
HUP9600623A2 (en) Herbicidally active tetrazoline derivatives, preparation and use thereof, and herbicide compositions containing these compounds as active ingredients
ZA791765B (en) New benzodioxole derivatives,processes for their preparation and their use as synergistic agents in insecticidal and acaricidal compositions
NO950950L (no) Farmasöytisk preparat
DE59205998D1 (de) Arzneimittel mit antineoplastischer Wirkung enthaltend als Wirkstoff Octadecyl-[2-(N-methylpiperidino)-ethyl]-phosphat und Verfahren zu dessen Herstellung
EP0435186A3 (en) Pyridyloxypyrimidine derivatives, preparation process thereof, and herbicidal compositions containing the same as active ingredients
IL57058A (en) Dichlorobenzodioxole derivatives,their preparation and their use as synergistic agents in insecticidal and acaricidal compositions
MX9303588A (es) Herbicidas novedosos.
ES2181023T3 (es) Uso de una combinacion de cloramina-t y acido propionico en productos alimentarios para animales.
IT8349565A0 (it) Composti fisiologicamente attivi,loro derivati, procedimenti per la loro preparazione e prodotti farmaceutici che li contengono come principi attivi
IE780730L (en) Veterinary composition
IT1232796B (it) Composizioni sinergisticamente attive e procedimento per la loro preparazione.

Legal Events

Date Code Title Description
FB Suspension of granting procedure